Nonalcoholic steatohepatitis (NASH) drugs market

被引：54
|
作者：
Cassidy, Sorcha [1 ]
Syed, Basharut A. [1 ]
机构：
[1] PSL Grp, FirstWord Pharma, 75 Davies St, London W1K 5JN, England
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 11期
关键词：
D O I：
10.1038/nrd.2016.188
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [21] Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
    Z. Wang
    Z. Zhao
    Y. Xia
    Z. Cai
    C. Wang
    Y. Shen
    R. Liu
    H. Qin
    J. Jia
    G. Yuan
    Journal of Endocrinological Investigation, 2022, 45 : 1379 - 1392
  • [22] Targeting USP24 in nonalcoholic steatohepatitis, NASH
    Hung, Jan-jong
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 436 - 436
  • [23] COMPLEX ROLE OF OSTEOPONTIN IN THE PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS (NASH)
    Jindal, A.
    Sutti, S.
    Locatelli, I.
    Chiocchetti, A.
    Soluri, M. F. F.
    Vacchiano, M.
    Maldi, E.
    Bozzola, C.
    Dianzani, U.
    Albano, E.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S512 - S512
  • [24] Glucose tolerance in children and adolescents with nonalcoholic steatohepatitis (NASH)
    Ciampalini, P
    Nobili, V
    Cappa, M
    Sartorelli, MR
    Barbetti, F
    DIABETES, 2004, 53 : A427 - A427
  • [25] ADIPOHORMONES AS PROGNOSTIC MARKERS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
    Krawczyk, K.
    Szczesniak, P.
    Kumor, A.
    Jasinska, A.
    Omulecka, A.
    Pietruczuk, M.
    Orszulak-Michalak, D.
    Sporny, S.
    Malecka-Panas, E.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2009, 60 : 71 - 75
  • [26] A new method to induce nonalcoholic steatohepatitis (NASH) in mice
    Savari, Feryal
    Mard, Seyyed Ali
    Badavi, Mohammad
    Rezaie, Anahita
    Gharib-Naseri, Mohammad Kazem
    BMC GASTROENTEROLOGY, 2019, 19 (1)
  • [27] Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
    Wang, Z.
    Zhao, Z.
    Xia, Y.
    Cai, Z.
    Wang, C.
    Shen, Y.
    Liu, R.
    Qin, H.
    Jia, J.
    Yuan, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (07) : 1379 - 1392
  • [28] The Central Zone "Portalization" Phenomenon in Nonalcoholic Steatohepatitis (NASH)
    Oliver-Krasinski, J. M.
    Peruyero, L. C.
    Moreira, R. K.
    MODERN PATHOLOGY, 2012, 25 : 420A - 421A
  • [29] Serum markers of fibrogenesis and fibrosis in nonalcoholic steatohepatitis (NASH).
    Costanzo, M
    Miele, L
    Di Rocco, P
    Forgione, A
    Alfei, B
    Pompili, M
    Rapaccini, GL
    Grieco, A
    Gasbarrini, G
    HEPATOLOGY, 2002, 36 (04) : 412A - 412A
  • [30] The role of liver MTP activity in nonalcoholic steatohepatitis (NASH)
    Fujita, Koji
    Imajyo, Kento
    Nozaki, Yuichi
    Yoneda, Masato
    Kirikoshi, Hiroyuki
    Saito, Satoru
    Wada, Koichiro
    Nakajima, Atsushi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 28P - 28P
12345